CD274 and neoplasm: The possibility of qualification of such treatments is decided by the patients’ performance status or stage of the disease, but the predictive factors for the combination therapy with immunotherapy, such as PD-L1 expression on tumor cells or tumor mutation burden (TMB) have not been sufficiently studied.